Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.39
-0.01 (-0.07%)
At close: Mar 9, 2026, 4:00 PM EDT
14.39
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 87.27B INR in the quarter ending December 31, 2025, with 4.41% growth. This brings the company's revenue in the last twelve months to 345.83B, up 11.09% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
345.83B INR
Revenue Growth
+11.09%
P/S Ratio
3.02
Revenue / Employee
12,435,044 INR
Employees
27,811
Market Cap
11.63B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Viatris | 14.30B |
| Elanco Animal Health | 4.72B |
| United Therapeutics | 3.18B |
| Amneal Pharmaceuticals | 3.02B |
| Neurocrine Biosciences | 2.86B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
RDY News
- 16 hours ago - What is dragging Dr Reddy’s shares 2% down today? Explained - Business Upturn
- 3 days ago - Top stocks to watch today, March 6: TCS, Tata Elxsi, GE Shipping, GRSE, Dr Reddy’s Lab, Mazagon Dock, Wipro, Bharat Forge, Angel One in focus - Business Upturn
- 4 days ago - Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's - Nasdaq
- 10 days ago - Top losers among Nifty 50 stocks in midday trades today, Feb 27: Dr. Reddy’s falls 2.8%, Bharti Airtel down 2.7%, Grasim Industries drops 2.5% - Business Upturn
- 10 days ago - Pharma sector stocks today, Feb 27: Dr. Reddys Lab down 1.14%, Cipla falls 1.04%, Natco Pharma up 1.09% - Business Upturn
- 12 days ago - Citi flags Ozempic price cuts as negative for Dr Reddy’s generic Semaglutide uptake - Business Upturn
- 17 days ago - Dr. Reddy's (RDY) Biosimilar Application for Orencia Accepted by FDA - GuruFocus
- 17 days ago - Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept - Business Wire